2017考研英語(yǔ)沖刺:仿真題閱讀模擬1

最后更新時(shí)間:2016-11-28 09:44:48
輔導(dǎo)課程:暑期集訓(xùn) 在線(xiàn)咨詢(xún)
復(fù)習(xí)緊張,焦頭爛額?逆風(fēng)輕襲,來(lái)跨考秋季集訓(xùn)營(yíng),幫你尋方法,定方案! 了解一下>>
  關(guān)鍵詞:2017考研英語(yǔ) 英語(yǔ)閱讀模擬

  在距離2017考研不足30天的情況下,按照經(jīng)驗(yàn)來(lái)說(shuō),這個(gè)時(shí)候小伙伴們應(yīng)該都在玩命的背政治刷真題做模擬,雖說(shuō)這個(gè)時(shí)候英語(yǔ)作文是英語(yǔ)提分的大項(xiàng),但是作為考研英語(yǔ)分值的重頭戲——閱讀不容忽視,小編帶來(lái)了英語(yǔ)閱讀模擬題,并在文章底部配以答案,希望能對(duì)考生的復(fù)習(xí)有所幫助!

  At 18, Ashanthi DeSilva of suburban Cleveland is a living symbol of one of the great intellectual achievements of the 20th century. Born with an extremely rare and usually fatal disorder that left her without a functioning immune system (the “bubble-boy disease,” named after an earlier victim who was kept alive for years in a sterile plastic tent), she was treated beginning in 1990 with a revolutionary new therapy that sought to correct the defect at its very source, in the genes of her white blood cells. It worked. Although her last gene-therapy treatment was in 1992, she is completely healthy with normal immune function, according to one of the doctors who treated her, W. French Anderson of the University of Southern California. Researchers have long dreamed of treating diseases from hemophilia to cancer by replacing mutant genes with normal ones. And the dreaming may continue for decades more. “There will be a gene-based treatment for essentially every disease,” Anderson says, “within 50 years.”

  It's not entirely clear why medicine has been so slow to build on Anderson's early success. The National Institutes of Health budget office estimates it will spend $432 million on gene-therapy research in 2005, and there is no shortage of promising leads. The therapeutic genes are usually delivered through viruses that don't cause human disease. “The virus is sort of like a Trojan horse,” says Ronald Crystal of New York Presbyterian/Weill Cornell Medical College. “The cargo is the gene.”

  At the University of Pennsylvania's Abramson Cancer Center, immunologist Carl June recently treated HIV patients with a gene intended to help their cells resist the infection. At Cornell University, researchers are pursuing gene-based therapies for Parkinson's disease and a rare hereditary disorder that destroys children's brain cells. At Stanford University and the Children's Hospital of Philadelphia, researchers are trying to figure out how to help patients with hemophilia who today must inject themselves with expensive clotting drugs for life. Animal experiments have shown great promise.

  But somehow, things get lost in the translation from laboratory to patient. In human trials of the hemophilia treatment, patients show a response at first, but it fades over time. And the field has still not recovered from the setback it suffered in 1999, when Jesse Gelsinger, an 18-year-old with a rare metabolic disorder, died after receiving an experimental gene therapy at the University of Pennsylvania. Some experts worry that the field will be tarnished further if the next people to benefit are not patients but athletes seeking an edge. This summer, researchers at the Salk Institute in San Diego said they had created a “marathon mouse” by implanting a gene that enhances running ability; already, officials at the World Anti-Doping Agency are preparing to test athletes for signs of “gene doping.” But the principle is the same, whether you're trying to help a healthy runner run faster or allow a muscular-dystrophy patient to walk. “Everybody recognizes that gene therapy is a very good idea,” says Crystal. “And eventually it's going to work.”

  21. The case of Ashanthi Desilva is mentioned in the text to ____________.

  [A] show the promise of gene-therapy

  [B] give an example of modern treatment for fatal diseases

  [C] introduce the achievement of Anderson and his team

  [D] explain how gene-based treatment works

  22. Anderson‘s early success has ________________.

  [A] greatly speeded the development of medicine

  [B] brought no immediate progress in the research of gene-therapy

  [C] promised a cure to every disease

  [D] made him a national hero

  23. Which of the following is true according to the text?

  [A] Ashanthi needs to receive gene-therapy treatment constantly.

  [B] Despite the huge funding, gene researches have shown few promises.

  [C] Therapeutic genes are carried by harmless viruses.

  [D] Gene-doping is encouraged by world agencies to help athletes get better scores.

  24. The word “tarnish” (line 5, paragraph 4) most probably means ____________.

  [A] affect

  [B] warn

  [C] trouble

  [D] stain

  25. From the text we can see that the author seems ___________.

  [A] optimistic

  [B] pessimistic

  [C] troubled

  [D] uncertain

  答案:A B C D A

     如果你對(duì)翻身方案還有迷茫,如果你對(duì)自身的復(fù)習(xí)結(jié)果沒(méi)有足夠的信心,如果你想要最后時(shí)刻還能搏擊目標(biāo)院校,那么跨考沖刺押題保分,幫你考點(diǎn)押題,給你內(nèi)部資料,將會(huì)是你最后沖刺押題保分的不二的選擇!
報(bào)名參加沖刺押題保分  了解沖刺押題保分
相關(guān)推薦
復(fù)習(xí)指導(dǎo) 2017考研大綱及解析原文 2017考研公共課最后時(shí)刻保分通道
考研時(shí)間 跨考教育整理——2017年考研時(shí)間表 考研報(bào)名及現(xiàn)場(chǎng)確認(rèn)流程
真題分?jǐn)?shù)線(xiàn) 2016考研真題及答案解析 歷年考研國(guó)家線(xiàn)匯總(跨考教育整理)

  2022考研初復(fù)試已經(jīng)接近尾聲,考研學(xué)子全面進(jìn)入2023屆備考,跨考為23考研的考生準(zhǔn)備了10大課包全程準(zhǔn)備、全年復(fù)習(xí)備考計(jì)劃、目標(biāo)院校專(zhuān)業(yè)輔導(dǎo)、全真復(fù)試模擬練習(xí)和全程針對(duì)性指導(dǎo);2023考研的小伙伴針也已經(jīng)開(kāi)始擇校和復(fù)習(xí)了,跨考考研暢學(xué)5.0版本全新升級(jí),無(wú)論你在校在家都可以更自如的完成你的考研復(fù)習(xí),暑假集訓(xùn)營(yíng)帶來(lái)了院校專(zhuān)業(yè)初步選擇,明確方向;考研備考全年規(guī)劃,核心知識(shí)點(diǎn)入門(mén);個(gè)性化制定備考方案,助你贏在起跑線(xiàn),早出發(fā)一點(diǎn)離成功就更近一點(diǎn)!

點(diǎn)擊右側(cè)咨詢(xún)或直接前往了解更多

考研院校專(zhuān)業(yè)選擇和考研復(fù)習(xí)計(jì)劃
2023備考學(xué)習(xí) 2023線(xiàn)上線(xiàn)下隨時(shí)學(xué)習(xí) 34所自劃線(xiàn)院??佳袕?fù)試分?jǐn)?shù)線(xiàn)匯總
2022考研復(fù)試最全信息整理 全國(guó)各招生院校考研復(fù)試分?jǐn)?shù)線(xiàn)匯總
2023全日制封閉訓(xùn)練 全國(guó)各招生院??佳姓{(diào)劑信息匯總
2023考研先知 考研考試科目有哪些? 如何正確看待考研分?jǐn)?shù)線(xiàn)?
不同院校相同專(zhuān)業(yè)如何選擇更適合自己的 從就業(yè)說(shuō)考研如何擇專(zhuān)業(yè)?
手把手教你如何選專(zhuān)業(yè)? 高校研究生教育各學(xué)科門(mén)類(lèi)排行榜

跨考考研課程

班型 定向班型 開(kāi)班時(shí)間 高定班 標(biāo)準(zhǔn)班 課程介紹 咨詢(xún)
秋季集訓(xùn) 沖刺班 9.10-12.20 168000 24800起 小班面授+專(zhuān)業(yè)課1對(duì)1+專(zhuān)業(yè)課定向輔導(dǎo)+協(xié)議加強(qiáng)課程(高定班)+專(zhuān)屬規(guī)劃答疑(高定班)+精細(xì)化答疑+復(fù)試資源(高定班)+復(fù)試課包(高定班)+復(fù)試指導(dǎo)(高定班)+復(fù)試班主任1v1服務(wù)(高定班)+復(fù)試面授密訓(xùn)(高定班)+復(fù)試1v1(高定班)
2023集訓(xùn)暢學(xué) 非定向(政英班/數(shù)政英班) 每月20日 22800起(協(xié)議班) 13800起 先行階在線(xiàn)課程+基礎(chǔ)階在線(xiàn)課程+強(qiáng)化階在線(xiàn)課程+真題階在線(xiàn)課程+沖刺階在線(xiàn)課程+專(zhuān)業(yè)課針對(duì)性一對(duì)一課程+班主任全程督學(xué)服務(wù)+全程規(guī)劃體系+全程測(cè)試體系+全程精細(xì)化答疑+擇校擇專(zhuān)業(yè)能力定位體系+全年關(guān)鍵環(huán)節(jié)指導(dǎo)體系+初試加強(qiáng)課+初試專(zhuān)屬服務(wù)+復(fù)試全科標(biāo)準(zhǔn)班服務(wù)

①凡本網(wǎng)注明“稿件來(lái)源:跨考網(wǎng)”的所有文字、圖片和音視頻稿件,版權(quán)均屬北京尚學(xué)碩博教育咨詢(xún)有限公司(含本網(wǎng)和跨考網(wǎng))所有,任何媒體、網(wǎng)站或個(gè)人未經(jīng)本網(wǎng)協(xié)議授權(quán)不得轉(zhuǎn)載、鏈接、轉(zhuǎn)帖或以其他任何方式復(fù)制、發(fā)表。已經(jīng)本網(wǎng)協(xié)議授權(quán)的媒體、網(wǎng)站,在下載使用時(shí)必須注明“稿件來(lái)源,跨考網(wǎng)”,違者本網(wǎng)將依法追究法律責(zé)任。

②本網(wǎng)未注明“稿件來(lái)源:跨考網(wǎng)”的文/圖等稿件均為轉(zhuǎn)載稿,本網(wǎng)轉(zhuǎn)載僅基于傳遞更多信息之目的,并不意味著再通轉(zhuǎn)載稿的觀點(diǎn)或證實(shí)其內(nèi)容的真實(shí)性。如其他媒體、網(wǎng)站或個(gè)人從本網(wǎng)下載使用,必須保留本網(wǎng)注明的“稿件來(lái)源”,并自負(fù)版權(quán)等法律責(zé)任。如擅自篡改為“稿件來(lái)源:跨考網(wǎng)”,本網(wǎng)將依法追究法律責(zé)任。

③如本網(wǎng)轉(zhuǎn)載稿涉及版權(quán)等問(wèn)題,請(qǐng)作者見(jiàn)稿后在兩周內(nèi)速來(lái)電與跨考網(wǎng)聯(lián)系,電話(huà):400-883-2220